Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Xalacom · 5 trials · 5 indications
Value at Week 8 minus value at baseline
| Arm | Type | Description |
|---|---|---|
| Xalatan | EXPERIMENTAL | - |
| Xalacom | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Xalatan | DRUG | latanoprost 0.005%, one rop once daily in evening |
| Xalacom | DRUG | latanoprost 0.005% adn timolol 0.5%, one drop, once daily |
| Timolol | DRUG | - |
| unfixed Latanoprost and Timolol | DRUG | - |
Inclusion Criteria: * Intraocular pressure is 18 mmHg or more at baseline after treatment with Xalatan for 4 weeks or more. Exclusion Criteria: * History of no-response to timolol * History of trabeculectomy * History of other ocular surgery including ALT, SLT,and trabeculotomy within 6 months
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
Xalacom is used for the treatment of glaucoma, including open angle glaucoma, and ocular hypertension. It is an ophthalmology product developed by Pfizer, Inc. and has been studied in Phase 3 clinical trials involving patients with these conditions.
Xalacom is made by Pfizer, Inc., which trades under the ticker symbol PFE. Pfizer is the developer responsible for the clinical development of Xalacom.
Xalacom is in Phase 3 clinical development. It is an investigational product and has not been approved by the FDA. The Phase 3 program includes four trials, all of which are completed.
Xalacom has been evaluated in four Phase 3 clinical trials. These include NCT00383019, NCT00277498, NCT00219596, and NCT00159653. The trials enrolled a total of 2,244 participants and studied Xalacom in patients with glaucoma or ocular hypertension.
Xalacom and Xalatan are not the same. Xalatan is a separate product that was used as a comparator in a Phase 3 trial of Xalacom. Xalacom is a fixed combination therapy, while Xalatan is a single-agent treatment.